A Look At MicroPort Scientific (SEHK:853) Valuation After New Global Distribution Agreements

MicroPort Scientific (SEHK:853) has drawn fresh attention after its group entered into two international distribution framework agreements that set very large potential annual transaction caps for cardiovascular, CRM, and related products across multiple overseas regions. See our latest analysis for MicroPort Scientific. At a share price of HK$9.44, MicroPort Scientific has seen a 2.16% 1 day share price return and a 24.05% 90 day share price decline. The 1 year total shareholder return of 39.44% contrasts with weaker multi year results, which suggests recent momentum has cooled after a sharp rebound from earlier losses. If this kind of international expansion has your attention, it can be worth broadening your watchlist to other healthcare names tapping into AI driven opportunities via our 127 healthcare AI stocks. With MicroPort reporting revenue of US$994.9 million, a loss of US$233.8 million, and trading on what external models suggest is roughly a 48% discount to intrinsic value, is the current price a chance to buy, or is the market already giving credit for future growth? Preferred Price to Sales Multiple of 2.3x: Is it justified? MicroPort Scientific is trading on a P/S of 2.3x, which current models suggest is consistent with a share price that sits well below some fair value estimates. The P/S multiple compares the company’s market value to its revenue, which can be useful for medical equipment businesses that are still loss making. With revenue of US$994.9 million and a reported loss of US$233.8 million, investors are effectively paying for the top line while the bottom line remains negative. Several indicators point to the market assigning a relatively low sales multiple. MicroPort Scientific is described as trading at good value compared to peers and the wider industry, with its 2.3x P/S sitting against a peer average of 14.6x and a Hong Kong Medical Equipment industry average of 4.6x. A fair P/S level from regression based work is indicated at 3.4x, which is above where the shares currently trade and highlights a valuation level the market could potentially move toward if sentiment improves. Explore the SWS fair ratio for MicroPort Scientific Result: Price-to-sales of 2.3x (UNDERVALUED) However, there are clear risks, including the current US$233.8 million loss and heavy reliance on China and Europe, which could amplify any regulatory or reimbursement setbacks. Find out about the key risks to this MicroPort Scientific narrative. Another way to look at value On the other side of the ledger, the SWS DCF model points to a fair value of about HK$18.13 per share, compared with the current HK$9.44 price. This implies MicroPort Scientific is trading at a roughly 48% discount. If both methods indicate it looks inexpensive, what might the market be concerned about? Look into how the SWS DCF model arrives at its fair value. 853 Discounted Cash Flow as at Apr 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out MicroPort Scientific for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 230 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps Given the mixed signals so far, it makes sense to look at the full picture yourself and decide how the balance of risks and rewards stacks up. Then review the 3 key rewards Looking for more investment ideas? If you stop with just one stock, you risk missing other opportunities that could better match your goals, risk comfort, and timeframe, so keep widening your search. Target rock solid balance sheets and steady fundamentals with the Simply Wall Street solid balance sheet and fundamentals stocks screener (385 results). Hunt for potential value opportunities that combine quality and pricing support using the curated 230 high quality undervalued stocks. Spot under the radar companies with strong metrics before the crowd catches on by checking the focused screener containing 565 high quality undiscovered gems. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for Free